Last updated on November 2018

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Brief description of study

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Clinical Study Identifier: NCT02092467

Contact Investigators or Research Sites near you

Start Over

Pfizer Call Center

Tiervlei Trial Centre, Karl Bremer Hospital
Bellville, Cape Town, South Africa
  Connect »

Pfizer Call Center

Panorama Medical Centre.
Cape Town, South Africa
  Connect »